Evidence map›Paper›PMID 31347480›Full record

Observational studyThe British journal of psychiatry : the journal of mental science2019

Effect of lifestyle, medication and ethnicity on cardiometabolic risk in the year following the first episode of psychosis: prospective cohort study.

Fiona Gaughran, Daniel Stahl, Dominic Stringer, David Hopkins, Zerrin Atakan, Kathryn Greenwood, Anita Patel, Shubulade Smith, Poonam Gardner-Sood, John Lally and 11 more

Registry-linked trialOpen access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in The British journal of psychiatry : the journal of mental science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04792268 (Implementation of an Electronic Clinical Decision Support System), which is not on this map. Cited by 16 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 3 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04792268 nacompletednot on this mapstarted 2022, after this paper: background citation

Implementation of an Electronic Clinical Decision Support System (eCDSS) for the Early Recognition and Management of Diabetes and Dysglycaemia in Secondary Mental Healthcare : Feasibility Study

TypeinterventionalSponsorKing's College LondonRan2022 to 2023Enrolled4ConditionsSevere Mental Disorder, Diabetes Mellitus, Dysglycemia, Staff AttitudeArmsAccess to eCDSS on wards
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 9 institutions in 5 countries.

Fiona GaughranLead Consultant Psychiatrist, National Psychosis Service, South London and Maudsley NHS Foundation Trust; and Reader, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, Denmark Hill, UK.
Daniel StahlProfessor in Medical Statistics and Statistical Learning, Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK.
Dominic StringerStatistician, Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK.
David HopkinsConsultant Diabetologist, Institute Director and Clinical Academic Group Lead, Institute of Diabetes, Endocrinology and Obesity, King's Health Partners, UK.
Zerrin AtakanSenior Lecturer, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK.
Kathryn GreenwoodProfessor of Clinical Psychology, School of Psychology, University of Sussex, UK.
Anita PatelDirector, Anita Patel Health Economics Consulting Ltd; and Honorary Professor, Queen Mary University of London, UK.
Shubulade SmithClinical Senior Lecturer, Department of Forensic and Neurodevelopmental Science, Institute of Psychiatry, Psychology and Neuroscience, Kings College London; and Consultant Psychiatrist, Forensic Services, South London and Maudsley NHS Foundation Trust, UK.
Poonam Gardner-SoodClinical Trials Manager, University College London, UK.
John LallyVisiting Researcher, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK; and the Royal College of Surgeons in Ireland.ORCID 0000-0003-3038-0625
Margaret HeslinResearch Fellow and Honorary Lecturer, Kings' Health Economics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK.ORCID 0000-0002-3094-9255
Brendon StubbsNIHR Lecturer, Department of Psychological Medicine, Institute of Psychiatry, King's College London; and Head of Physiotherapy, Physiotherapy Department, South London and Maudsley NHS Foundation Trust, UK.
Stefania BonaccorsoConsultant Psychiatrist, C&I Foundation Trust; and Visiting Lecturer, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK.
Anna KolliakouClinical Informatics Interface and Network Lead, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK.
Oliver HowesProfessor of Molecular Psychiatry, MRC London Institute for Medical Sciences; and Institute of Psychiatry, Psychology and Neuroscience, Kings College London; and the South London and Maudsley NHS Foundation Trust, UK.
David TaylorDirector of Pharmacy and Pathology and Head of Pharmaceutical Sciences Clinical Academic Group, King's Health Partners, South London and Maudsley NHS Foundation Trust, UK.
Marta Di FortiMRC Clinician Scientist, Department of Social, Genetic and Developmental Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, Kings College London; the South London and Maudsley NHS Foundation Trust, UK; and Department of Psychiatry, Experimental Biomedicine and Clinical Neuroscience (BIONEC), University of Palermo, Italy.
Anthony S DavidProfessor of Mental Health, Director and Sackler Chair, Institute of Mental Health, Division of Psychiatry, University College London, UK.
Robin M MurrayProfessor of Psychiatric Research, Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, Kings College London; the South London and Maudsley NHS Foundation Trust, UK; and Department of Psychiatry, Experimental Biomedicine and Clinical Neuroscience (BIONEC), University of Palermo, Italy.
Khalida IsmailProfessor of Psychiatry and Medicine, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, UK.
IMPACT team
King's College London · GBKing's College - North Carolina · USInstitute of Mental Health · GBKings Health Partners · GBMRC Clinical Trials Unit at UCL · GBQueen Mary University of London · GBRoyal College of Surgeons in Ireland · IESouth London and Maudsley NHS Foundation Trust · GBUniversity of Sussex · GB

Funding

Department of Health ICA-CL-2017-03-001Medical Research Council G0700995Medical Research Council MC_U120097115Medical Research Council MR/L022176/1Medical Research Council MR/N026063/1Medical Research Council MR/N027078/1
6 · The paper itself

Abstract

backgroundThe first episode of psychosis is a critical period in the emergence of cardiometabolic risk.

aimsWe set out to explore the influence of individual and lifestyle factors on cardiometabolic outcomes in early psychosis.

methodThis was a prospective cohort study of 293 UK adults presenting with first-episode psychosis investigating the influence of sociodemographics, lifestyle (physical activity, sedentary behaviour, nutrition, smoking, alcohol, substance use) and medication on cardiometabolic outcomes over the following 12 months.

resultsRates of obesity and glucose dysregulation rose from 17.8% and 12%, respectively, at baseline to 23.7% and 23.7% at 1 year. Little change was seen over time in the 76.8% tobacco smoking rate or the quarter who were sedentary for over 10 h daily. We found no association between lifestyle at baseline or type of antipsychotic medication prescribed with either baseline or 1-year cardiometabolic outcomes. Median haemoglobin A1c (HbA1c) rose by 3.3 mmol/mol in participants from Black and minority ethnic (BME) groups, with little change observed in their White counterparts. At 12 months, one-third of those with BME heritage exceeded the threshold for prediabetes (HbA1c >39 mmol/mol).

conclusionsUnhealthy lifestyle choices are prevalent in early psychosis and cardiometabolic risk worsens over the next year, creating an important window for prevention. We found no evidence, however, that preventative strategies should be preferentially directed based on lifestyle habits. Further work is needed to determine whether clinical strategies should allow for differential patterns of emergence of cardiometabolic risk in people of different ethnicities.

Indexed as

Life StyleAdolescentAdultAgedAntipsychotic AgentsCardiovascular DiseasesEthnicityFemaleGlycated HemoglobinHumansMaleMiddle AgedObesityPrediabetic StateProspective StudiesPsychotic DisordersAntipsychotic AgentsGlycated Hemoglobincardiometabolic riskethnicityFirst episode psychosisglucose dysregulationweight

Identifiers

PMID31347480
PMCPMC7557635
OpenAlexW2957343693

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.